한글목차

이 보고서는 비호지킨림프종 시장을 조사하고 CAR T 세포 치료, 이중특이성 항체 및 BTK 억제제의 효능과 미래 잠재력에 대한 주요 인사이트를 포함한 현재 및 새로운 치료법에 대한 상세한 분석을 제공합니다. 또한, 비호지킨림프종 치료의 최신 동향, 과제 및 발전 사항을 검토하여 의료진과 연구자들에게 귀중한 정보를 제공할 것입니다.

목차

주요 요약

현재 및 향후 치료 알고리즘

조사 목적

CAR T 세포 치료

• 미만성 대세포형 B세포 림프종
  • Yescarta(axicabtagene ciloleucel, Gilead), Bryanzi(lisocabtagene maraleucel, BMS) 및 Kymriah(tisagenlecleucel, Novartis)
• 여포성 림프종
  • Yescarta(axicabtagene ciloleucel, Gilead), Bryanzi(lisocabtagene maraleucel, BMS) 및 Kymriah(tisagenlecleucel, Novartis)
• 외투세포림프종
  • Tecartus(brexucabtagene autoleucel, Gilead) 및 Breyanzi(lisocabtagene maraleucel, BMS)
• 차세대 CAR T 세포 치료
  • 주요 인사이트 요약

T세포에 작용하는 이중특이성항체(BsAbs)

• 여포성 림프종
  • Lunsumio(mosunetuzumab, Roche), Epkinly/Tepkinly(epcoritamab, AbbVie/Genmab), Columvi(glofitamab, Roche) 및 odronextamab(Regeneron)
• 미만성 대세포형 B세포 림프종
  • Epkinly/Tepkinly(epcoritamab, AbbVie/Genmab), Columvi(glofitamab, Roche), Lunsumio(mosunetuzumab, Roche), and odronextamab(Regeneron)
• 외투세포림프종 및 변연부림프종
  • Epkinly/Tepkinly(epcoritamab, AbbVie/Genmab), Columvi(glofitamab, Roche), Lunsumio(mosunetuzumab, Roche) 및 odronextamab(Regeneron)

항체약물접합체(ADC)

• 승인된 약제
  • Polivy(polatuzumab vedotin, Roche)
  • Zynlonta(loncastuximab tesirine, ADC Therapeutics/Sobi)

단클론항체(mAbs)

• 승인된 약제
  • Monjuvi/Minjuvi(tafasitamab, Incyte)

BCL-2 억제제(9)

• 파이프라인 약제
  • Venclexta/Venclyxto(venetoclax, AbbVie/Roche)

BTK 억제제(16)

• 승인된 약제(16)
  • Brukinsa(zanubrutinib, BeiGene), Calquence(acalabrutinib, AstraZeneca), Imbruvica(ibrutinib, AbbVie/J&J) 및 Jaypirca(pirtobrutinib, Lilly)

향후 치료 동향

• 주요 인사이트 요약

부록

KOL 보고서

영문목차

This Non-Hodgkin's Lymphoma (NHL) Therapy Trends report provides a detailed analysis of current and emerging therapies. It includes insights from leading Key Opinion Leaders (KOLs) on the efficacy and future potential of CAR T-cell therapy, bispecific antibodies, and BTK inhibitors. The report examines the latest trends, challenges, and advancements in NHL treatment, offering valuable information for healthcare professionals and researchers. It aims to inform on the evolving landscape of NHL management, supported by data-driven findings and expert opinions.

Table of Contents

Executive summary

Current and future treatment algorithms

Research objectives

CAR T-cell therapies

• Diffuse large B-cell lymphoma
  • Yescarta (axicabtagene ciloleucel; Gilead), Breyanzi (lisocabtagene maraleucel; BMS) and Kymriah (tisagenlecleucel; Novartis)
• Follicular lymphoma
  • Yescarta (axicabtagene ciloleucel; Gilead), Breyanzi (lisocabtagene maraleucel; BMS) and Kymriah (tisagenlecleucel; Novartis)
• Mantle cell lymphoma
  • Tecartus (brexucabtagene autoleucel; Gilead) and Breyanzi (lisocabtagene maraleucel; BMS)
• Next-generation CAR T-cell therapies
  • Key insights summary

T cell-engaging bispecific antibodies (BsAbs)

• Follicular lymphoma
  • Lunsumio (mosunetuzumab; Roche), Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche) and odronextamab (Regeneron)
• Diffuse large B-cell lymphoma
  • Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche), Lunsumio (mosunetuzumab; Roche), and odronextamab (Regeneron)
• Mantle cell lymphoma and marginal zone lymphoma
  • Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche), Lunsumio (mosunetuzumab; Roche) and odronextamab (Regeneron)

Antibody-drug conjugates (ADCs)

• Approved drugs
  • Polivy (polatuzumab vedotin; Roche)
  • Zynlonta (loncastuximab tesirine; ADC Therapeutics/Sobi)

Monoclonal antibodies (mAbs)

• Approved drugs
  • Monjuvi/Minjuvi (tafasitamab; Incyte)

BCL-2 inhibitors

• Pipeline drugs
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche)

BTK inhibitors

• Approved drugs
  • Brukinsa (zanubrutinib; BeiGene), Calquence (acalabrutinib; AstraZeneca), Imbruvica (ibrutinib; AbbVie/J&J) and Jaypirca (pirtobrutinib; Lilly)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe

KOL Bulletins